3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Head & Neck
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
19
Paclitaxel
6
Trastuzumab
5
Nivolumab
5
palbociclib
4
Carboplatin
4
Biopsy
4
lenvatinib
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Immunoglobulin G
3
Fulvestrant
3
Cyclophosphamide
3
Cetuximab
3
trastuzumab deruxtecan
2
tisotumab vedotin
2
spartalizumab
2
sargramostim
2
gedatolisib
2
fludarabine
2
epacadostat
2
capivasertib
2
X-Rays
2
Sunitinib
2
Docetaxel
2
Disulfides
2
Cisplatin
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Imlunestrant
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled